Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of IVX-411, a Receptor Binding Domain (RBD) SARS-CoV-2 (COVID-19) Virus-Like Particle (VLP) Vaccine, in Healthy SARS-CoV-2 Seronegative and Seropositive Adults (Part 2)

Next Previous
X
Search
Trial Profile

A Phase 1/2 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of IVX-411, a Receptor Binding Domain (RBD) SARS-CoV-2 (COVID-19) Virus-Like Particle (VLP) Vaccine, in Healthy SARS-CoV-2 Seronegative and Seropositive Adults (Part 2)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IVX-411 (Primary) ; MF 59
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Icosavax

    • Most Recent Events

    • 25 Mar 2022 Topline interim results published in an Icosavax Media Release.
    • 07 Jan 2022 According to an Icosavax media release, dosing in the Phase 1 (younger adults) portion has been completed and the Phase 1b (older adults) portion of this trial has been initiated. Interim, top-line data is expected in 1Q 2022.
    • 02 Dec 2021 Planned End Date changed from 22 Feb 2022 to 12 May 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top